Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/lyme-disease-treatment-market-862
Lyme Disease Treatment Market Taxonomy:
By disease type:
• Early Lyme disease (absence of erythema migrans)
• Lyme carditis
• Lyme arthritis
• neurologic Lyme disease
• Borrelial lymphocytosis
• Post-treatment Lyme Disease Syndrome (PTLDS)
By treatment:
• Doxycycline
• Amoxicillin
• Cefuroxime axetil
• Ceftriaxone
• Others (azithromycin, clarithromycin, erythromycin)
Increasing incidence to drive the Lyme disease treatment market in North America
Globally, North America accounts for largest share of the market, owing to the highest number
of Lyme disease cases reported here. According to Centers for Disease Control and Prevention
(CDC), around 28,453 confirmed cases of Lyme disease and 9 new cases per 1,00,000 people
were recorded in the U.S. during the 2005 - 2015. The European market is also expected to
experience rapid growth in the Lyme disease treatment market in near future. According to the
2014 factsheet of European Centre for Disease Prevention and Control (ECDC), prevalence of
Lyme disease is steadily increasing.
The major players operating in the Lyme disease treatment market include Lupin Ltd, Mylan
N.V., Sun Pharmaceuticals Industries Ltd., Pfizer Inc., G&W Laboratories, Inc., Teva
Pharmaceutical Industries Ltd., Sandoz AG, GlaxoSmithKline plc., and Hospira Inc.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/
buy-now/862